Filtered By:
Condition: Hemorrhagic Stroke
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 372 results found since Jan 2013.

Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation
This study aimed to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascu lar calcification, and vascular endothelial dysfunction. We studied 21 consecutive patients with persistent or chronic AF, who were treated with warfarin at least for 12 months. Warfarin administration was changed to rivaroxaban (10 or 15 mg/day) in all patients. Osteopontin (OPN), bone alkaline ph osphatase (BAP), and under-carboxylated osteocalcin (ucOC) were measured. Pulse wave velocity (PWV) and augmentation index (AI) were also measured as atherosclerosis assessments. All measurements were done before ...
Source: Heart and Vessels - February 22, 2017 Category: Cardiology Source Type: research

Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A  meta-analysis of randomized controlled trials
Conclusions In Asian patients with AF, NOACs, regardless of dosing regimens, have a similar feature of preserved efficacy with improved safety compared with warfarin.
Source: Journal of the Formosan Medical Association - June 21, 2017 Category: General Medicine Source Type: research

Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A  meta-analysis of randomized controlled trials.
CONCLUSIONS: In Asian patients with AF, NOACs, regardless of dosing regimens, have a similar feature of preserved efficacy with improved safety compared with warfarin. PMID: 28645443 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - June 20, 2017 Category: General Medicine Authors: Wang KL, Chiu CC, Su-Yin Tan D, Lin CY, Lai EY, Goto S, Giugliano RP, Chiang CE Tags: J Formos Med Assoc Source Type: research

Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage
Conclusions: DOAC-related ICH is associated with smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH.
Source: Neurology - September 11, 2017 Category: Neurology Authors: Tsivgoulis, G., Lioutas, V.-A., Varelas, P., Katsanos, A. H., Goyal, N., Mikulik, R., Barlinn, K., Krogias, C., Sharma, V. K., Vadikolias, K., Dardiotis, E., Karapanayiotides, T., Pappa, A., Zompola, C., Triantafyllou, S., Kargiotis, O., Ioakeimidis, M., Tags: Intracerebral hemorrhage ARTICLE Source Type: research

The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Conclusions -This study based meta-analysis shows that it may be both safer and more effective to use NOACs as compared with VKA to treat patients with non-valvular AF and concomitant aspirin therapy. PMID: 29101289 [PubMed - as supplied by publisher]
Source: Circulation - November 3, 2017 Category: Cardiology Authors: Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, Brueckmann M, Kleine E, Ten Berg JM Tags: Circulation Source Type: research

Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.
Authors: Joung B Abstract Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the...
Source: Korean Circulation Journal - November 26, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Use of Non –Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review
Semin Thromb Hemost DOI: 10.1055/s-0037-1607436This observational study aimed to investigate the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with malignancy. A total of 76 patients (mean age: 73.2 ± 8.9; 28 females) with AF and malignancy treated with NOAC were included in the analysis. The mean CHA2DS2-VASc and HAS-BLED scores were 3.2 ± 1.2 and 2.2 ± 0.9, respectively. The study population was taking dabigatran 150 mg (25%) twice daily (BID), apixaban 5 mg BID (25%), dabigatran 110 mg BID (24%), rivaroxaban 20 mg (18%) once a da...
Source: Seminars in Thrombosis and Hemostasis - December 8, 2017 Category: Hematology Authors: Russo, Vincenzo Rago, Anna Papa, Andrea Antonio Meo, Federica Di Attena, Emilio Golino, Paolo D'Onofrio, Antonio Nigro, Gerardo Tags: Review Article Source Type: research

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
CONCLUSIONS: Treatment with factor Xa inhibitors significantly reduced the number of strokes and systemic embolic events compared with warfarin in people with AF. The absolute effect of factor Xa inhibitors compared with warfarin treatment was, however, rather small. Factor Xa inhibitors also reduced the number of ICHs, all-cause deaths and major bleedings compared with warfarin, although the evidence for a reduction in the latter is less robust. PMID: 29509959 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 6, 2018 Category: General Medicine Authors: Bruins Slot KM, Berge E Tags: Cochrane Database Syst Rev Source Type: research

Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry – The TAC 2 Study
Conclusion: We found that the incidence of OAC-induced ICH was greater than in previous studies. Hemorrhage volume and mortality were lower in ICH-DOACs than in ICH-VKAs. After stroke, DOACs were the most frequently indicated antithrombotic treatment.Intervent Neurol 2018;7:284 –295
Source: Interventional Neurology - April 4, 2018 Category: Neurology Source Type: research

Slow Elevation in Protein C Activity without a PROC Mutation in a Neonate with Intracranial Hemorrhage
We report a case of hemorrhagic stroke associated with neonatal asphyxia and severe PC deficiency. Plasma PC and protein S activity 7 days after birth was 12% and 43%, respectively. No PROC mutation was found. PC levels did not exceed 20% until 2 months of age, even in the absence of consumption coagulopathy or vitamin K deficiency. Neither thromboembolic nor hemorrhagic events occurred during the infusion of activated PC concentrate (twice weekly, up to 68 days after birth). The PC activity levels gradually increased to the standard value for age by 9 months of age. The present case showed that neonatal PC deficiency with...
Source: American Journal of Perinatology Reports - April 12, 2018 Category: Perinatology & Neonatology Authors: Uehara, Erika Nakao, Hiro Tsumura, Yusuke Nakadate, Hisaya Amari, Shoichiro Fujinaga, Hideshi Tsutsumi, Yoshiyuki Kang, Dongchon Ohga, Shouichi Ishiguro, Akira Tags: Case Report Source Type: research

Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients: A retrospective propensity score matched cohort study
Vitamin K antagonists (VKAs) have been shown to decrease the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). [1] The non-VKA oral anticoagulants (NOACs) are now increasingly used as an alternative to VKAs thanks to their convenient, fixed dose and no requirement for monitoring. NOACs have shown non-inferiority to warfarin for the prevention of stroke and systemic embolism, with marked reduction in the risk of intracerebral haemorrhage [2].
Source: International Journal of Cardiology - April 25, 2018 Category: Cardiology Authors: Giacomo Zoppellaro, Luca Zanella, Gentian Denas, Nicola Gennaro, Eliana Ferroni, Ugo Fedeli, Seena Padayattil Jose, Giorgio Costa, Maria Chiara Corti, Margherita Andretta, Vittorio Pengo Source Type: research

Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”
During studies of anti-coagulants to prevent cardioembolic stroke, startling data emerged that patients treated with novel oral anti-coagulants (NOACs) appeared to suffer less brain hemorrhage than patients treated with traditional, vitamin-K depleting anticoagulants [1, 2]. That NOACs reduced the bleeding risk did not fit accepted dogma: clinicians imagine that hemorrhage occurs during and following ischemic stroke as the brain undergoes necrosis. In the presence of anti-coagulation, such necrotic bleeding ought to be augmented.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Patrick D. Lyden Tags: Editorial Source Type: research

Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing
Direct or new oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have recently revolutionized the field of antithrombotic therapy for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (NVAF). Randomized controlled trials have shown that these agents have at least comparable efficacy with vitamin K antagonists along with superior safety, at least in what concerns intracranial hemorrhage. As a result, NOACs are indicated as first-line anticoagulation therapy for NVAF patients with at least one risk f...
Source: Cardiology - July 5, 2018 Category: Cardiology Source Type: research

Prognostic factors and analysis of mortality due to brain haemorrhages associated with vitamin K antagonist oral anticoagulants. Results from the TAC Registry
ConclusionICH in patients treated with VKA is associated with high mortality rates; mortality in these patients is mainly and independently associated with the clinical situation at stroke onset.ResumenIntroducciónLa hemorragia intracraneal (HIC) en pacientes tratados con anticoagulantes orales antagonistas de la vitamina K (AVK) es una complicación grave y frecuentemente letal; en este trabajo estudiamos las características clínicas y los factores que se relacionan con la mortalidad en este grupo de pacientes.MétodosRealizamos un estudio observacional, multicéntrico y retrospectivo, de ámbito nacional, basado en re...
Source: Neurologia - July 8, 2018 Category: Neurology Source Type: research